Novel VLA-4 antagonists

IDrugs

Volumn 3, Issue 7, 2000, Pages 788-798

  Porter, John R ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001182073     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Hynes RO: Integrins: versatility, modulation and signalling in cell adhesion. Cell (1992) 69:11-25.
2. 4 integrin: an alternative pathway for neutrophil recruitment? Immunol Today (1999) 20:545-550.
3. Elices ME, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR: VCAM-1 on activated endothelium interact with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell (1990) 59:577-584.
4. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG: Identfication and characterization of the T-lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol (1989) 109:321-1330.
5. Bayless KJ, Meininger GA, Scholtz JM, Davis GE, Osteopontin is a ligand for the α4β1 integrin. J Cell Sci (1998) 111:1165-1174.
6. Isobe T, Hisaoka T, Shimizu A, Okuno M, Aimoto S, Takada Y, Saito Y, Takagi J: Propolypetide of von Willebrand factor is a novel ligand for VLA4 integrin. J Biol Chem (1997) 272:8447-8453.
7. Wang J- H, Pepinsky RB, Stehle T, Uu, J-H, Karpaus M, Browning B, Osborn L: The crystal structure of an N-terminal two domain fragment of VCAM-1: A cyclic peptide based on the domain 1 C-D loop can inhibit VCAM-1 α4β1 integrin interaction. Proc Natl Acad Sci USA (1995) 92:5714-5718.
8. Komoriya A, Green LJ, Mervic M, Yamada SS, Yamada KM, Humphries MJ: The minimal essential sequence for a major cell type specific adhesion site (CS-1) within the alternately spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J Cell Biol (1991) 266:15075-15079.
9. Jones EY, Harlos K, Bottomley MJ, Robinson RC, Driscoll PC, Edwards RM, Dudgeon TJ, Stuart DI: Crystal structure of an integrin binding fragment of VCAM-1. Nature (1995) 373:539-544.
10. Bergelson JM, Hemler ME: Do integrins use a MIDAS touch to grab an Asp? Curr Biol (1995) 5:615-617.
11. Springer TA: Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β-propeller domain. Proc Natl Acad Sci USA (1997) 94:65-72.
12. Elices MJ: The role of the integrin α4β1 in inflammation and the development of novel anti-inflammatory and antirheumatic agents. Rheumatoid Arthritis (1997) 1:642-646;
13. Foster CA: VCAM-1/α4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders. J Allergy Clin Immunol (1996) 98:S270-S277;
14. Elices MJ: Blockade of the VLA-4 integrin as a therapy for airway inflammation in respiratory disease. Curr Opin Anti-inflamm Immunomod Invest Drugs (1999) 1:14-20;
15. Elices MJ: Role of the integrin α4β1 in inflammatory disorders. In: Cell Adhesion Molecules and Matrix Proteins: Role in Health and Diseases. Mousa SA (Ed), Springer-Verlag and RG Landes Co (1998) 134-147.
16. Bochner BS: Targeting VLA-4 integrin function: Potential Therapeutic Implications. In: Cell Adhesion Molecules and Matrix Proteins: Role in Health and Diseases. Mousa SA (Ed), Springer-Verlag and RG Landes Co (1998) 113-131.
17. Donoghue S, Greenlees C: Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies - an update. Exp Opin Invest Drugs (2000) 9:167-171.
18. Zimmerman CN: Peptide and peptidomimetic inhibitors of VLA-4. Exp Opin Ther Pat (1999) 9:129-133;
19. Lobb RR, Adams SP: Small molecule antagonists of α4 integrins: novel drugs for asthma. Exp Opin Invest Drugs (1999) 8:935-945;
20. Adams SP, Lobb RR: Annu Rep Medicinal Chem (1999) 34:179-188;
21. Lin K-C, Castro AC: Very late antigen-4 (VLA-4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol (1998) 2:453-457.
22. Lin K-C, Ateeq HS, Hsiung SH, Chong LT, Zimmerman CN, Castro A, Lee, W-C, Hammond CE, Kalkunte K, Chen L-L, Pepinsky RB, Leone DR, Sprague AG, Abraham WM, Gill A, Lobb RR, Adams SP: Selective tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses. J Med Chem (1999) 42:920-934.
23. Chen LL, Whitty A, Lobb RR, Adams SP, Pepinsky RB: Multiple activation states of integrin α4β1 detected through their different affinities for a small molecule ligand. J Biol Chem (1999) 274:13167-13175.
24. Abraham WM, Sielczak MW, Ashfaq A, Cortes A, Lauredo IT, Kim J, Pepinsky B, Benjamin CD, Leone DR, Lobb RR, Weller PF: α4 Integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest (1994) 93:776.
25. Bolger GT: BIO-1211. Curr Opin Antiinflamm Immunomod Invest Drugs (2000) 2(2):108-112.
26. Chen LL, Lobb RR, Cuervo JH, Lin K-C, Adams SP, Pepinsky RB: Identification of ligand binding sites on integrin α4β1 through chemical cross-linking. Biochemistry (1998) 37:8743-8753.
27. Cliffe IA, Bebbington D, Gillespie RJ, Knutsen LJS: RSC-SCI - Tenth Medicinal Chemistry Symposium, Cambridge, UK. IDdb Meeting Report (1999) September 5-8.
28. Souers AJ, Vigilio AA, Schürer SS, Ellman JA, Kogan TP, West HE, Ankener W, Vanderslice P: Novel inhibitors of α4β1 integrin receptor interactions through library synthesis and screening. Bioorg Med Chem Lett (1998) 8:2297-2302.
29. Archibald SC, Head JC, Linsley J, Porter JR, Robinson MK, Shock A, Warrellow GJ: Discovery and evaluation of potent cysteine based α4β1 integrin antagonists. Bioorg Med Chem Lett (2000) 10:993-995;
30. Archibald SC, Head JC, Gozzard N, Howat DW, Parton AH, Porter JR, Robinson MK, Shock A, Warrellow GJ, Abraham WM: Discovery and evaluation of potent tyrosine based α4β1 integrin antagonists. Bioorg Med Chem Lett (2000) 10:997-999.
31. N-Acylphenylalanines as antagonists of VLA4/VCAM-1. Exp Opin Ther Pat (1999) 9:1443-1446.
32. Treegarden BR, Rishton GM, Tamagishi M, Jayakumar H, Lobl TJ, Cadarelli P, Gorcsan F, Castro M, Evans BR, Riley DT, Tanis SP, Thomas JF, Harrison AW, Alexander DL, McGrath JP: Discovery of TR-9109: A novel small molecule inhibitor of α4β1 integrin mediated cell adhesion. ACS (1999) 218 New Orleans MEDI 58.
33. Agathangelou P: American Chemical Society 218th National meeting: Medicinal Chemistry poster highlights. IDdb Meeting Report (1999) 216 August 22-26.
34. Sircar I, Gudmundsson KS, Martin R, Nomura S, Jayakumar H, Nowlin DM, Cardarelli PM, Mah JR, Castro MA, Cao Y, Griffith RC, Lazarides E: Discovery of TR-14035: An orally dual active α4β7/α4β1 integrin antagonist. ACS (1999) 218 New Orleans MEDI 59
35. Martin R, Sircar I, Liang JT, Nomura S, Morningstar MM, Gudmundsson, Nowlin DM, Cardarelli PM, Mah JR, Connell SA, Castro MA, Cao Y, Griffith RC, Lazarides E: SAR of TR-14035: An orally active dual α4β7/α4β1 integrin antagonist. ACS (1999) 218 New Orleans MEDI 60.
36. Furth PS, Chiang SL, Sircar I, Griffith RC, Nowlin D, Gorscan Mah J, Lazarides E: Parallel synthesis optimisation of TR-14035. A dual active α4β7/α4β1 integrin antagonist: generation of α4β1 selective antagonists. ACS (1999) 218 New Orleans MEDI 61.
37. Hutton I: American Chemical Society 218th National meeting: Medicinal Chemistry poster highlights. IDdb Meeting Report (1999) 218 August 22-26.
38. Shroff, HN, Schwender CF, Baxter AD, Brookfield F, Payne LJ, Cochran NA, Gallant DL, Briskin MJ: Novel modified tripeptide inhibitors of α4β7 mediated lymphoid cell adhesion to MAdCAM-1. Bioorg Med Chem Lett (1998) 8:1601-1606.
39. Andrew DP, Berlin C, Honda S, Yoshino T, Hamann A, Holzmann B, Kilshaw PJ, Butcher EC: Distinct but overlapping epitopes are involved in α4β7 mediated adhesion to VCAM-1, MAdCAM-1, fibronectin and lymphocyte aggregation. J Immunol (1994) 153:3847-3861;
40. Briskin MJ, McEvoy LM, Butcher EC: MAdCAM-1 has homology to immunoglobulin and mucin like adhesion receptors and to IgA1. Nature (1993) 363:461-464;
41. Shyjan AM, Bertagnolli M, Kenney CJ, Briskin MJ: Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the α4β7 integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences. J Immunol (1996) 156:2851-2857.
42. Holzmann B, McIntyre BW Weissmann IL: Identification of a murine Peyers patch-specific lymphocyte homing receptor as an integrin molecule with an α chain homologous to human VLA4 α. Cell (1989) 56:37-46.
43. Taooka Y, Chen J, Yednock T, Sheppard D: The integrin α9β1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through intraction with vascular cell adhesion molecule-1. J Cell Biol (1999) 145:413-419.
44. BIOGEN INC (Lee W-C, Gill A): A novel VLA-4 inhibitor: oMePUPA-V. WO-09961421 (1999).
45. BIOGEN INC (Adams SP, Lin K-C, Lee W-C, Castro AC, Zimmerman CN, Hammond CE, Liao Y-S, Cuervo JH, Singh J): Cell adhesion inhibitors. WO-09622966 (1996).
46. RHÔNE-POULENC RORER LTD (Astles PC, Clark DE, Collis AJ, Cox PJ, Eastwood PJ, Harris NV, Lai JYQ, Morley AD, Porter B): Substituted anilides. WO-09923063 (1999).
47. RHÔNE-POULENC RORER LTD (Astles PC, Harris NV, Morley AD): Substituted beta-alanines. WO-09933789 (1999).
48. RHÔNE-POULENC RORER LTD (McCarthy C, Harris NV, Morley AD): Substituted diamines and their use as cell adhesion inhibitors. WO-09954321 (1999).
49. NOVARTIS AG (Wattanasin S, von Matt PJ): VLA-4 antagonists. WO-09937605 (1999).
50. ZENECA GROUP PLC (Brittain DR, Johnstone C): Chemical compounds. WO-09924398 (1999).
51. ZENECA GROUP PLC (Brittain DR, Johnstone C, Davies GM, Large MS): Chemical compounds. WO-00005223 (2000).
52. ZENECA GROUP PLC (Brittain DR, Johnstone C, Davies GM, Large MS): Chemical compounds. WO-00005224 (2000).
53. PFIZER PRODUCTS INC (Duplantier AJ, Milici AJ, Chupak LS): Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases. WO-00000477 (2000).
54. TEXAS BIOTECHNOLOGY CORP (Scott IL, Bore RG, Biediger RJ): Compounds that inhibit the binding of integrins to their receptors. WO-09952493 (1999)
55. TEXAS BIOTECHNOLOGY CORP (Kassir JM, Biediger RJ, Grabbe VO, Lin S, Market RV, Raju BG, Scott IL, Kogan TP): N,N-disubstituted amides that inhibit the binding of integrins to their receptors. WO-09952898 (1999).
56. HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (Wehner I, Stilz HU, Schmidt W, Seiffge D): Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them. EP-00903353 (1999)
57. HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (Wehner I, Stilz HU, Schmidt W, Seiffge D): 5 Ring heterocyles, process for preparation, use as inhibitors of leukocyte adhesion and pharmaceutical preparations comprising them. EP-00905139 (1999).
58. HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (Wehner V, Stilz HU, Schmidt W, Seiffge D): Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them. EP-00918059 (1999).
59. HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (Neises B, Wehner V, Stilz HU): Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same. WO-09960015 (1999).
60. CYTEL CORP (Arrhenius TS, Elices MJ, Gaeta FCA, He Y-B, Huyghe BG, Chen PG): CS-1 peptidomimetics, compositions and method of using the same. WO-00002903 (2000).
61. MERCK & CO INC (Durette PL, Hagmann WK, MacCoss M, Mills SG, Mumford RA): Sulfonamides as cell adhesion inhibitors. WO-09853818 (1998).
62. MERCK & CO INC (Durette PL, Hagmann WK, MacCoss M, Mills SG, Mumford RA): Biarylalkanoic acids WO-09853817 (1998).
63. MERCK & CO INC (Durette PL, Hagmann WK, MacCoss M, Mills SG, Mumford RA, van Riper GM, Schmidt JA, Kevin NJ): Heterocyclic amide compounds as cell adhesion inhibitors. WO-09853814 (1998).
64. MERCK & CO INC (Chang L, Hagmann WK, Macoss M): Substituted pyrrole derivatives as cell adhesion inhibitors. WO-09926922 (1999).
65. MERCK & CO INC (Delaszlo SE): Azapeptide acids as cell adhesion inhibitors.WO-09920272 (1999).
66. MERCK & CO INC (Chang L, Hagmann WK, Macoss M): Cyclic amino acid derivatives as cell adhesion inhibitors. WO-09926615 (1999).
67. MERCK & CO INC (Durette PL, Hagmann WK, Kopka IE, Macoss M, Mills SG, Mumford RA, Magriotis PA): Substituted beta-alanine derivatives as cell adhesion inhibitors. WO-09926921 (1999).
68. MERCK & CO INC (Delaszlo SE, Hagmann WK): Paraaminomethylaryl carboxamide derivatives. WO-09926923 (1999).
69. MERCK & CO INC (Delaszlo SE, Hagmann WK): 4-Substituted-4-piperidine carboxamide derivatives. WO-09925685 (1999).
70. ATHENA NEUROSCIENCES INC, AMERICAN HOME PRODUCTS CORP (Thorsett ED, Semko CM, Sarantakis D, Pleiss MA, Kreft A, Konradi AW, Grant FS, Dressen DB, Ashwell S et al): Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4. WO-09906390 (1999);
71. ATHENA NEUROSCIENCES INC, AMERICAN HOME PRODUCTS CORP (Thorsett ED, Semko CM, Sarantakis D, Pleiss MA, Kreft A, Konradi AW, Grant FS, Dressen DB et al): Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4.WO-09906431 (1999);
72. ATHENA NEUROSCIENCES INC, AMERICAN HOME PRODUCTS CORP (Thorsett ED, Semko CM, Pleiss MA, Lombardo LJ, Grant FS, Dressen DB, Dappen MS): Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4. WO-09906432 (1999);
73. ATHENA NEUROSCIENCES INC, AMERICAN HOME PRODUCTS CORP (Dappen MS, Dressen DB, Grant FS, Pleiss MA, Robinson CY, Sarantakis D, Thorsett ED): Compounds which inhibit leukocyte adhesion mediated by VLA-4. WO-09906433 (1999);
74. ATHENA NEUROSCIENCES INC, AMERICAN HOME PRODUCTS CORP (Ashwell S, Grant FS, Konradi AW, Kreft A, Lombardo LJ, Pleiss MA, Sarantakis D, Semko CM, Thorsett ED): 4-Aminophenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4. WO-09906434 (1999);
75. ATHENA NEUROSCIENCES INC, AMERICAN HOME PRODUCTS CORP (Ashwell S, Grant FS, Konradi AW, Krett A, Lombardo LJ, Pleiss MA, Sarantakis D, Semko CM, Thorsett ED): Dipeptide compounds which inhibit leukocyte adhesion mediated by VLA-4. WO-09906435 (1999);
76. ATHENA NEUROSCIENCES INC, AMERICAN HOME PRODUCTS CORP (Thorsett ED, Semko CM, Pleiss MA, Lombardo LJ, Konradi AW, Grant FS, Dressen DB, Dappen MS): Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4. WO-09906436 (1999);
77. ATHENA NEUROSCIENCES INC, AMERICAN HOME PRODUCTS CORP (Thorsett ED, Semko CM, Pleiss MA, Kreft A, Konradi AW, Grant FS, Baudy RB, Sarantakis D): Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by VLA-4. WO-09906437 (1999).
78. CELLTECH THERAPEUTICS LTD (Head JC, Archibald SC, Warrellow GJ): Anti-inflammatory tyrosine derivatives. WO-09854207 (1998).
79. CELLTECH THERAPEUTICS LTD (Head JC, Archibald SC, Warrellow GJ, Porter JR): Phenylalanine derivatives. WO-09935163 (1999).
80. CELLTECH THERAPEUTICS LTD (Head JC, Archibald SC, Warrellow GJ, Porter JR): Thiocarboxamide derivatives and their use as inhibitors of α-4 integrins. WO-09948879 (1999).
81. CELLTECH THERAPEUTICS LTD (Archibald SC, Head JC, Warrellow GJ, Porter JR): Cinnamic acid derivatives having cell adhesion modulating activity. WO-09947547 (1999).
82. CELLTECH THERAPEUTICS LTD (Head JC, Archibald SC, Warrellow GJ, Porter JR): Phenylalanine derivatives having VLA-4 antagonistic activity. WO-09961465 (1999).
83. CELLTECH THERAPEUTICS LTD (Head JC, Warallow GJ, Porter JR, Archibald SC): Aromatic amine derivatives as pharmaceutical agents. WO-09962901 (1999).
84. PHARMACIA & UPJOHN CO (Blinn JR, Chrusciel RA, Fisher JF, Tanis SP, Thomas EW, Lobl TJ, Teegarden BR): Inhibitors of α4β1 mediated cell adhesion. WO-09967230 (1999).
85. HOFFMANN-LA ROCHE AG (Chen L, Guthrie RW, Huang T-N, Hull KG, Sidduri A, Tilley JW): N-aroylphenylalanine derivatives. WO-09910313 (1999).
86. TANABE SEIKAYU CO LTD; PHARMACIA & UPJOHN CO (Lobl TJ, Rishton G, Teegarden B, Polinsky A, Yamagishi M, Tanis SP, Fisher JF, Thomas EW, Chrusciel RA): Inhibitors of α4β1 mediated cell adhesion. WO-09858902 (1998).
87. CELLTECH THERAPEUTICS LTD (Head JC, Archibald SC, Warrellow GJ, Porter JR): Phenylalanine derivatives useful as pharmaceutical agents. WO-09937618 (1999).
88. CELLTECH THERAPEUTICS LTD (Archibald SC, Head JC, Warrellow GJ, Porter JR): Phenylalanine derivatives as inhibitors of α4 integrins. WO-09943642 (1999).
89. CELLTECH THERAPEUTICS LTD (Porter JR, Head JC, Archibald SC, Warrellow GJ): Phenylalanine derivatives as integrin inhibitors. WO-09964390 (1999).
90. F HOFFMANN-LA ROCHE AG (Chen L, Guthrie RW, Huang T-N, Hull KG, Sidduri A, Tilley JW): N-alkanoylphenylalanine derivatives. WO-09910312 (1999).
91. TANABE SEIKAYU CO LTD (Sircar I, Gudmundsson KS, Martin R): Inhibitors of α4 mediated cell adhesion. WO-09936393 (1999).
92. ATHENA NEUROSCIENCES INC (Yednock TA, Pleiss MA): α-9 integrin antagonists and anti-inflammatory compositions thereof. WO-09906391 (1999).